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Abstract
Transplantation of a donor cornea to restore vision is the most frequently performed trans-
plantation in the world. Corneal endothelial cells (CEC) are crucial for the outcome of a graft
as they maintain corneal transparency and avoid graft failure due to corneal opaqueness.
Given the characteristic of being a monolayer and in direct contact with culture medium dur-
ing cultivation in eye banks, CEC are specifically suitable for gene therapeutic approaches
prior to transplantation. Recombinant adeno-associated virus 2 (rAAV2) vectors represent
a promising tool for gene therapy of CEC. However, high vector titers are needed to achieve
sufficient gene expression. One of the rate-limiting steps for transgene expression is the
conversion of single-stranded (ss-) DNA vector genome into double-stranded (ds-) DNA.
This step can be bypassed by using self-complementary (sc-) AAV2 vectors. Aim of this
study was to compare for the first time transduction efficiencies of ss- and scAAV2 vectors
in CEC. For this purpose AAV2 vectors containing enhanced green fluorescent protein
(GFP) as transgene were used. Both in CEC and in donor corneas, transduction with
scAAV2 resulted in significantly higher transgene expression compared to ssAAV2. The dif-
ference in transduction efficiency decreased with increasing vector titer. In most cases, only
half the vector titer of scAAV2 was required for equal or higher gene expression rates than
those of ssAAV2. In human donor corneas, GFP expression was 64.7±11.3% (scAAV) and
38.0±8.6% (ssAAV) (p<0.001), respectively. Furthermore, transduced cells maintained
their viability and showed regular morphology. Working together with regulatory authorities,
a translation of AAV2 vector-mediated gene therapy to achieve a temporary protection of
corneal allografts during cultivation and transplantation could therefore become more
realistic.
PLOS ONE | DOI:10.1371/journal.pone.0152589 March 29, 2016 1 / 14
OPEN ACCESS
Citation: Gruenert AK, Czugala M, Mueller C,
Schmeer M, Schleef M, Kruse FE, et al. (2016) Self-
Complementary Adeno-Associated Virus Vectors
Improve Transduction Efficiency of Corneal
Endothelial Cells. PLoS ONE 11(3): e0152589.
doi:10.1371/journal.pone.0152589
Editor: Giovanni Di Pasquale, National Institutes of
Health, UNITED STATES
Received: January 4, 2016
Accepted: March 16, 2016
Published: March 29, 2016
Copyright: © 2016 Gruenert et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any
medium, provided the original author and source are
credited.
Data Availability Statement: All relevant data are
within the paper.
Funding: Two of the authors [M. Schleef and M.
Schmeer] are employed by a commercial company:
PlasmidFactory GmbH & Co (http://www.
plasmidfactory.com). The funder provided support in
the form of salaries for authors [MS and MS], but did
not have any additional role in the study design, data
collection and analysis, decision to publish, or
preparation of the manuscript. The specific roles of
these authors are articulated in the ‘author
contributions’ section. The confocal microscope
Introduction
Corneal endothelial cells (CEC) form a monolayer on the posterior surface of the cornea and
are of fundamental relevance for vision. Their pump function is essential to maintain corneal
transparency by deswelling the corneal stroma [1–3]. As human CEC practically do not prolif-
erate [4], their decrease below a critical minimum unavoidably results in swelling of the cornea
leading to corneal opaqueness and ultimately to functional blindness. Moreover, both viability
and density of endothelial cells are the most relevant parameters in evaluation of donor corneas
processed in eye banks to supply the 300,000+ transplantations performed worldwide each
year. These criteria define the suitability of donor corneas for transplantation and further
determine the probability of graft survival and risk of re-transplantation [5, 6].
Thanks to distinct properties the corneal endothelium is a very attractive target for gene and
cell therapeutic approaches: 1. its monolayer structure results in direct contact of every single
cell to the culture medium ex vivo or to the aqueous humour of the anterior ocular chamber in
vivo; 2. its avascularity and immune privilege reduce the risk of immune reactions [7, 8]; 3.
compulsory processing of donor corneas in eye banks prior to engraftment over one to four
weeks opens the possibility of ex vivo gene therapy. Possible applications of gene delivery to the
corneal endothelium include immune modulation to prevent corneal graft rejection and
improving corneal allograft survival by protecting the endothelial monolayer from culture- and
transplant-associated apoptosis [9, 10].
Recombinant adeno-associated virus (rAAV) vectors provide a promising alternative to
other viral vectors and gene delivery systems, as they are nonpathogenic, replication-deficient
and transduce both dividing and non-dividing cells [11, 12]. Additionally, in contrast to lenti-
viral vectors which we have used in our previous studies [13, 14], AAV is non-integrating, thus
increasing its safety and conforming to regulatory requirements. Various cell types and tissues
can be efficiently transduced by AAV including liver [15], muscle [16], lung [17], CNS [18]
and bone marrow [19]. In the eye, practically all studies on AAV-mediated gene therapy were
performed to establish therapies targeting gene defects in the retina [20–23]. Successful trans-
duction, however, has also been demonstrated in the trabecular meshwork in glaucoma
research [24–26], in corneal stroma [27, 28] and in corneal endothelium [29–31].
In conventional AAV vectors, the genome is packaged as a linear single-stranded (ss) DNA
molecule with a length of approximately 4.7 kb. These single strands occur either in plus- or in
minus-form. Prior to gene expression, it is necessary to convert ssDNA into double-stranded
(ds) DNA either by strand annealing of one plus- and one minus-strand or by de novo synthe-
sis of DNA. This is known to be one of the rate-limiting steps for efficient transduction [32–
34]. Application of self-complementary (sc) AAV vectors allows a complete bypass of this issue
as these vectors contain a dimeric inverted repeat genome able to fold into dsDNA [32]. How-
ever, packing all complementary bases in the same virus particle limits the coding capacity of
scAAV to about half of that of ssAAV [32].
Previous studies have shown increased transduction efficiencies with scAAV [35–39]. As
the relative advantage of scAAV in comparison to ssAAV varies among different cell types, the
aim of this study was to analyze whether and by which extent transduction efficiencies in CEC
could be increased by the use of scAAV. This is of high relevance for a potential use of AAV in
ex vivo corneal gene therapy during cultivation of corneas in eye banks. Furthermore, CEC via-
bility following GFP insertion by the different AAV vector types was controlled.
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Methods
Cell culture / organ culture conditions
The human corneal endothelial cell line (HCEC-12, DMSZ No. ACC-646) was acquired from
Leibniz Institute DSMZ-German Collection of Microorganisms and Cell Cultures (Braun-
schweig, Germany) in 2012. Passages 18 to 22 were used for all experiments. Cells were trypsi-
nized (Trypsin/EDTA Solution 0.25% / 0.02% in PBS; Biochrom, Berlin, Germany) and seeded
in a 48-well plate containing 500 μl of culture medium at 60% confluency. Culture medium
was composed of Minimal Essential Medium (MEM; Sigma-Aldrich, St. Louis, MO, USA) with
5% fetal bovine serum (FBS) and 0.5% gentamicin (Sigma-Aldrich). Cells were incubated in a
humidified atmosphere at 37°C and 5% CO2. To maintain the cells, culture medium was
changed every other day.
Research-grade human donor corneas with intact endothelium cultivated at 4°C in Optisol
GS (Bausch&Lomb, Bridgewater, NJ, USA) were obtained from Indiana Lions Eye Bank (Indi-
anapolis, IN, USA; n = 4). Prior to transduction, corneoscleral buttons were transferred to
37°C organ-culture and pre-incubated in 4 ml culture medium containing FBS, epidermal
growth factor (EGF) and bovine pituitary extract (BPE), similar to Chen’s medium [40].
Transduction of CEC
Ss- and scAAV2 vectors containing the GFP gene driven by a cytomegalovirus (CMV) pro-
moter were kindly provided by Prof. Dr. H. Büning (Center for Molecular Medicine Cologne
(CMMC), Laboratory for AAV vector development, University of Cologne, Cologne, Ger-
many). Vector preparations were produced by plasmid co-transfection of Human Embryonic
Kidney (HEK) 293 cells as previously described [41]. As plasmids, either pssGFP or pscGFP
were used together with pXX [42] and pRC [43]. Cells were harvested, centrifuged, lysed and
treated with benzonase. The lysate was purified using an iodixanol density gradient. Vector
suspensions were obtained by extracting the 40% iodixanol phase and aliquoted without fur-
ther dilution or concentration.
24 hours after seeding of HCEC-12 cells, culture medium was replaced by 300 μl of fresh
medium and vector suspension was added according to the desired vector titer (day 0).
Human donor corneas with intact endothelium and high cell count unsuitable for trans-
plantation in humans were used according to the Erlangen University Ethic Committee
approval and to the Declaration of Helsinki. Each cornea was cut into six pieces and put into
separate wells of a 48-well plate. 500 μl of fresh medium and the respective amount of vector
suspension were added (day 0).
HCEC-12 cells and human corneal tissue were incubated with the vector suspension for 48
hours at 37°C and 5% CO2. After washing off the vector (day 2), culture media were replaced
every other day.
Evaluation of transgene expression
GFP expression in HCEC-12 cells was analyzed by flow cytometry (FACS Canto II with FACS-
Diva software, BD Biosciences, San Jose, CA, USA) directly after the transduction period (day
2) as well as on days 5, 8, 12, 16, 22 and 28. Three independent experiments were performed
for each vector titer and for each point of time. Supernatants and trypsinized cells were trans-
ferred to 15ml tubes on ice followed by centrifugation (3 minutes, 1200 rpm) and resuspension
of the cells in FACS buffer (PBS with 10% FCS). A total of 20,000 cells per sample were
analyzed.
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GFP expression in corneal tissue (n = 4) was evaluated by confocal microscopy at 200X
magnification on day 6 (Zeiss LSM 780 Confocal Microscope, Jena, Germany; six random
microscopic fields per corneal piece). After washing (PBS containing Ca2+ and Mg2+) and
fixation (4% paraformaldehyde in PBS, 15 minutes), cell membranes were marked using
rabbit anti-ZO-1 antibodies diluted 1:200 (Thermo Fisher Scientific, Waltham, MA, USA)
and goat-anti-rabbit IgG (H+L) conjugated to Alexa Fluor 647 (Jackson ImmunoResearch
Laboratories, West Grove, PA, USA) at a dilution of 1:500. Subsequently, corneal samples
were stained with DAPI (1 mg/ml, dilution 1:1500 in PBS) and mounted on glass slides
endothelial side up with Vectashield mounting medium (Vector Laboratories, Burlingame,
CA, USA).
Cell viability and metabolism evaluation
To assess viability of transduced CEC, HCEC-12 cells were harvested at the end of transduc-
tion (day 2).Three independent experiments were performed for each vector titer (25,000,
50,000 and 100,000 genomic particles of infection (GOI = AAV-capsids containing vector
DNA). Supernatants and trypsinized cells were transferred to 15ml tubes on ice followed by
centrifugation (3 minutes, 1200 rpm). After centrifugation, cells were resuspended in 200 μl
FACS-Buffer containing 2.5 μg/ml PO-PROTM-1 iodide (Thermo Fisher Scientific) and 5μg/
ml 7-AAD (7-Aminoactinomycin D, Sigma-Aldrich). PO-PROTM-1 and 7-AAD are DNA-
intercalating dyes which are impermeant to membranes of living cells. While PO-PROTM-1
can permeate through slightly impaired cell membranes of apoptotic cells 7-AAD is only
permeant to dead cells. Therefore, these dyes are used to discriminate vital cells with intact
cell membrane from apoptotic and dead cells allowing quantification by flow cytometry.
Non-transduced HCEC-12 cells seeded on the same day served as negative controls. Flow
cytometry was performed using FACS Canto II with FACS DIVA software. A total of 20,000
cells per sample were analyzed.
To study the metabolic state of transduced CEC, MTT (3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide)-assay was performed immediately after transduction (day
2). Culture medium was removed and replaced by fresh culture medium containing 0.5 mg/ml
MTT (Sigma Aldrich). Viable, metabolically active cells reduce MTT into purple colored for-
mazan, which can be measured quantitatively in terms of absorbance. After incubation at 37°C
and 5% CO2 for 2 hours, MTT solution was removed and resulting formazan was dissolved in
300 μl DMSO (Sigma Aldrich). Colorimetric analysis was performed using a spectrophotome-
ter (Multiskan Spectrum, Thermo Fisher Scientific).
In human donor corneas DNA strand breaks of apoptotic cells were labeled using TUNEL
(terminal deoxynucleotidyl transferase (TdT)-mediated deoxyuridine triphosphate (dUTP)-X
nick end labeling)-assay (In Situ Cell Death Detection Kit, TMR red, Roche Diagnostics
GmbH, Mannheim, Germany) according to the manufacturer’s instructions. Evaluation was
performed using confocal microscopy.
Statistical analysis
Statistical analysis was performed using GraphPad Prism (Version 6.01). Means and standard
deviations (SD) were calculated. Comparisons between two groups were performed using Stu-
dent’s t-test or Wilcoxon test. Multiple comparisons were performed using one-way ANOVA
test. P-values lower than 0.05 were considered statistically significant ( = p<0.05;  = p<0.01;
 = p<0.001).
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Results
GFP expression in HCEC-12 cells
To study transduction efficiencies following transduction with ss- and scAAV2, HCEC-12 cells
were treated with vector titers ranging from 1,000 to 100,000 GOI. In general, the amount of
GFP expressing cells detected by flow cytometry increased with increasing vector titer. Use of
scAAV2 resulted in significantly higher transgene expression levels compared to ssAAV2.
Fig 1 shows the amount of GFP expressing HCEC-12 cells 5 days after transduction with
equal titers of ss- or scAAV2. The difference between transduction efficiencies of ss- and
scAAV2 was greater for lower vector titers and smaller for higher vector titers. Using 1,000
GOI, the amount of GFP expressing cells on day 5 was 4.8-fold higher with scAAV2 compared
to ssAAV2 (p = 0.25). Using 10,000 GOI, scAAV2 lead to a 1.8-fold higher transduction rate
(p = 0.002), and using 100,000 GOI, the transduction rate with scAAV2 was merely 8% higher
than with ssAAV2 (p = 0.04).
To determine the kinetics of GFP expression, flow cytometry analyses were performed over
a period of 28 days. Results are presented in Fig 2(A) (vector titers 1,000–10,000 GOI) and Fig
2(B) (vector titers 25,000–100,000 GOI). Both vectors yielded a rapid onset of transgene
expression. 48 hours after transduction, GFP expression levels in cells transduced with ssAAV2
ranged from 3.7% ± 0.4% (1,000 GOI) to 67.3% ± 2% (100,000 GOI), while GFP expression lev-
els following transduction with scAAV2 ranged from 10.8% ±1% (1,000 GOI) to 75.3% ± 1,7%
(100,000 GOI). For most titers, the GFP expression peak was reached on day 5. The highest
transgene expression levels observed were 80.5% (ssAAV2) and 86.9% (scAAV2), respectively
(Fig 2(B)).
After transduction with 1,000 to 10,000 GOI ssAAV2, GFP expression levels peaked on day
2 and decreased afterwards (Fig 2(A)). In scAAV2, however, transduction with equal vector
titers lead to increasing expression levels until day 5. Between days 5 and 8 the amount of GFP
Fig 1. GFP expression of HCEC-12 cells five days after transduction (flow cytometry).Means and
standard deviations of three independent experiments are shown. GFP expression after transduction with
scAAV was significantly higher compared to ssAAV2 (* = p<0.05, ** = p<0.01).
doi:10.1371/journal.pone.0152589.g001
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expressing cells decreased again by factor 3 (2.6–3.4). After 12 days, expression levels were
below 5%.
Transductions with 25,000 to 100,000 GOI resulted in a more moderate loss of GFP expres-
sion between days 5 and 8 (Fig 2(B)). Use of higher vector titers resulted in sustained GFP
expression compared to lower vector titers: While cells transduced with 100,000 GOI lost 10%
(scAAV2) to 22% (ssAAV2) of GFP expression, cells transduced with 25,000 GOI of ssAAV2
showed almost 50% reduction in GFP-positivity until day 8.
Furthermore, GFP expression was prolonged by using scAAV. 12 days after transduction
with 100,000 GOI scAAV2, 35.3% of the cells still expressed the transgene. At that time, maxi-
mum expression level for ssAAV2 was 12.1%. Afterwards, expression levels in both groups fur-
ther decreased and dropped below 7% by day 28.
In almost all cases, application of only half the titer of scAAV resulted in equal or higher
transgene expression levels compared to ssAAV2 (Fig 2(A) and 2(B)). For lower vector titers,
the difference of dose-response relationship and therefore transduction efficiency was even
more evident: 1,000 GOI of scAAV2 yielded higher expression levels than 5,000 GOI of
ssAAV2 (p = 0.25). To confirm and visualize these findings, confocal microscopy of HCEC-12
cells seeded on chamber slides was performed (Fig 3).
GFP expression in CEC of human corneas
Six days after transduction (100,000 GOI per corneal piece) confocal microscopy showed sig-
nificantly higher GFP expression in the scAAV2 group compared to the ssAAV2 group (64.7
±11.3% versus 38.0±8.6%, p<0.001) (Fig 4(A) and 4(B)).
Viability and metabolism of transduced cells
In all studied groups, there was no significant difference between cell viability of transduced
and untreated cells. Neither the amount of 7-AAD positive (dead) or PO-PRO 1 positive
Fig 2. GFP-expression levels of transduced HCEC-12 cells over time (flow cytometry).Means and standard deviations of three independent
experiments are shown. (A) vector titers 1,000-10,000 GOI; (B) vector titers 25,000–100,000 GOI.
doi:10.1371/journal.pone.0152589.g002
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(apoptotic) cells detected by flow cytometry (p = 0.062 and p = 0.578) (Fig 5) nor the metabolic
activity quantified by MTT-test (p = 0.415) (Fig 6) significantly differed from negative control.
Fig 3. Confocal microscopy images of HCEC-12 cells transduced with different vector titers two days after transduction. (A) cells transduced with
ssAAV2; (B) cells transduced with scAAV2.
doi:10.1371/journal.pone.0152589.g003
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Confocal microscopy of human corneas transduced with ss- or sc-AAV showed regular cell
morphology with intact cell membranes (visualized by ZO-1 staining). We could not detect sig-
nificant DNA-strand breaks by TUNEL-assay (Fig 4).
Fig 4. Confocal microscopy images of endothelial cells of human donor corneas six days after transduction. (A) transduced with 100,000 GOI
ssAAV2; (B) transduced with 100,000 GOI scAAV2. Six randommicroscopic fields per corneal piece were evaluated. For each vector, one exemplary
microscopic field is shown (blue = DAPI, green = GFP, pink = Alexa 647, red = TUNEL).
doi:10.1371/journal.pone.0152589.g004
Fig 5. Effect of vector titer on transduction efficiency and cell viability (measured by flow cytometry two days after transduction).Means and
standard deviations of three independent experiments are shown. (A) Transduced = GFP-positive cells. Transduction with scAAV2 resulted in significantly
higher GFP expression rates compared to ssAAV2 (** = p<0.01, *** = p<0.001). (B) Dead = 7-AAD-positive cells. There were no significant differences
between cells transduced with sc- and ssAAV2 or between transduced cells and negative controls (one-way ANOVA, p = 0.062). (C) Apoptotic = PO-PRO-
1-positive cells. There were no significant differences between cells transduced with sc- and ssAAV2 or between transduced cells and negative controls
(one-way ANOVA, p = 0.578).
doi:10.1371/journal.pone.0152589.g005
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Discussion
For the first time, it hereby could be demonstrated that scAAV2 shows a more efficient trans-
duction of human corneal endothelium compared to ssAAV2. Although studies have shown
substantial enhancement of gene delivery by using scAAV in numerous other tissues [35–39],
to date there were no data evaluating transduction of corneal endothelium with scAAV. These
novel findings have significant potential to establish a gene therapeutic approach for ex vivo
cultivated donor corneas processed in eye banks prior to transplantation.
Previous studies working on CEC and ssAAV reported transduction efficiencies ranging
from 2% (rabbit and human corneas) to 96% (human corneas) [29, 30, 44]. Differences in
transduction could be explained by use of different AAV serotypes as well as by different tro-
pism in different species. In our current study, the maximum transgene expression level
achieved in human corneal endothelial cells was 80.5%, compared to about 38% in one of our
previous studies [29]. In earlier work of our group using a different ssAAV2 vector we observed
a late onset of transgene expression and an increased GFP expression 19 days after transduc-
tion [29]. On the contrary, we could now detect remarkable levels of GFP expression as early as
after two days in the same cell type. This illustrates both dependency and impact of the vector
preparation (ssAAV from two different vector cores) on the gene expression outcome. Interest-
ingly, the level of GFP expression rapidly decreased after day 5, while in the past study it con-
tinued to increase until day 23 [29]. Characteristically, CEC stop proliferation once the cells
reach complete confluency because of contact inhibition. Though having used the same cell
line and equal seeding conditions in both studies, it might be possible that CEC in the current
experiments show a higher proliferation tendency due to a lower passage number. Therefore,
with every cell division vector DNA was distributed among the two daughter cells and conse-
quently transgene expression levels dropped over time. This, however, would not solely explain
the considerable differences in onset and kinetics of GFP overexpression.
Fig 6. Metabolic activity of transduced cells as a sign of cell viability (analyzed by MTT-assay two
days after transduction).Means and standard deviations of three independent experiments are shown.
There was no significant difference between transduced cells and negative controls (one-way ANOVA;
p = 0.415).
doi:10.1371/journal.pone.0152589.g006
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Alternatively, the use of different culture media for transduction and subsequent organ-cul-
ture might deliver an explanation: Culture medium enriched with growth factors for example
leads to increased efficiency of gene delivery (96% with growth factors versus 19% without
growth factors) [30]. In our study, we used a similar culture medium containing growth factors.
On day 6, we observed transgene expression in 38.0±8.6% of CEC transduced with ssAAV.
To date, there are no studies evaluating the use of scAAV in corneal endothelial cells. How-
ever, in a glaucoma study aiming to transduce the trabecular meshwork of living rats and mon-
keys by intracameral injection of scAAV2, strong GFP expression in CEC was observed as a
side effect. GFP-positivity in the corneal endothelium was present for at least 19 days after
injection [25]. Unfortunately, GFP expression was not further quantified. Recently, a similar
glaucoma study reported mosaic-like to almost homogenous GFP-positivity in CEC four weeks
after injection of scAAV into the anterior chamber of mice and rats [26]. Transduction effi-
ciency was described by semiquantitative evaluation of intensity and of distribution of GFP
[45].
In our ex vivo study in human tissue, we successfully transduced 64.7±11.3% of CEC with
scAAV. This represents a 1.7 fold increase relative to ssAAV. In cultured CEC, use of scAAV
lead to a 4.8-fold increase in GFP-positivity compared to ssAAV. With rising vector titers, pre-
dominance in transduction efficiency of scAAV gradually diminished. These results are consis-
tent with other studies comparing ss- and scAAV in muscle and in the retina [22, 46]. These
tissues share their accessibility to local gene delivery and therefore the ability to isolate high
concentrations of vector in the immediate vicinity of target cells, which facilitates high multi-
plicity infection [32]. This in turn increases the probability of dsDNA-formation by strand
annealing or DNA synthesis [32, 47].
Transduction with scAAV not only resulted in higher, but also slightly more sustained
transgene expression than transduction with ssAAV. This could be due to generally higher lev-
els of gene expression with scAAV. Since a dsDNA genome is more stable than a ssDNA
genome, which can be degraded by cellular repair mechanisms after being recognized as dam-
aged DNA, transduction efficiency of ssAAV might be further limited compared to scAAV
[48, 49].
AAV is known to be nonpathogenic and several studies have proven its safety in ocular gene
therapy [50–53]. After in vivo transduction of CEC in rabbits no significant difference was
found between central corneal thickness of transduced corneas and negative controls, suggest-
ing that the pump function of CEC is not compromised by transduction with rAAV [31]. How-
ever, as rabbit corneal endothelium does show proliferative capacity [54–56], the suitability of
findings for use in humans could be questioned. According to our histological analysis, trans-
duction of CEC did not alter cell morphology. This is confirmed by others in histological analy-
ses of cryosectioned, H&E stained, ex vivo AAV transduced human corneas [30]. The number
of apoptotic cells in human corneas detected by TUNEL method did not differ significantly
from negative control. Furthermore, there was no significant difference in the percentage of
dead and apoptotic cells detected by flow cytometry and MTT-assay showed unchanged meta-
bolic activity.
Moreover, in an in vivo glaucoma study in rats and monkeys, no humoral or cellular-medi-
ated responses were observed in any of the transgene-expressing animals after intracameral
injection of scAAV2 [25].
The use of scAAV increases transduction efficiency in comparison to their single-stranded
counterparts by circumventing the rate-limiting step of second strand synthesis. This could be
overcome by using higher ssAAV titers, thus increasing the probability of strand-annealing of
two complementary single strands [32, 47]. However, with scAAV sufficient gene expression
levels can be achieved by far lower vector titers than with ssAAV. This can be accompanied by
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advantageous effects: 1. increase in safety of gene delivery by reducing the risk of possible
adverse effects and immune responses to the vector; 2. advances in practicability and in cost-
effectiveness. A considerable drawback of scAAV seems to be its limited packaging capacity of
about 2.5 kb. Therefore, the overall range of possible functional applications is limited to genes
smaller than this packaging size. This aspect has to be carefully taken into account and to be
weighed against the potential benefits of using scAAV [22, 32].
In conclusion, scAAV permits further optimization of AAV-mediated gene therapy of cor-
neal endothelium, if the desired transgene does not exceed a critical size. Areas of application
could include transduction of corneal allografts with anti-apoptotic genes, especially if trans-
lated to ex vivo treatment prior to transplantation. This would lead to the desired temporary
protection of corneal endothelium during one to four weeks of cultivation in eye banks. Hence,
discard rates of donor tissue being in short supply in most countries worldwide would be low-
ered, thus increasing transplantation figures. In addition, the rapid loss of endothelium directly
following transplantation could be limited, thus lowering graft failure and re-transplantation
rates. The elegant advantage of using AAV vectors is the gradual reduction of the anti-apopto-
tic effect within four weeks after transduction. By translating this approach into eye banking
and clinic, health economic expenses for corneal transplantations could be significantly
reduced.
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